|
Re: To those still complaining about flagging violations and removing posts.....
|
1
|
Resverlogix Corp.
|
Jun 23, 2016 05:29PM
|
|
Re: To those still complaining about flagging violations and removing posts.....
|
2
|
Resverlogix Corp.
|
Jun 23, 2016 05:57PM
|
|
Re: To those still complaining about flagging violations and removing posts.....
|
|
Resverlogix Corp.
|
Jun 23, 2016 08:05PM
|
|
Violation update
|
3
|
Resverlogix Corp.
|
Jun 24, 2016 08:07AM
|
|
Re: NR on phase 1 Kidney Trial
|
2
|
Resverlogix Corp.
|
Jan 23, 2017 02:04PM
|
|
Re: A little movie foreshadowing humor while we wait
|
2
|
Resverlogix Corp.
|
Feb 18, 2017 01:45PM
|
|
Re: A comment about market penetration
|
3
|
Resverlogix Corp.
|
Mar 19, 2017 01:16PM
|
|
Re: A comment about market penetration
|
2
|
Resverlogix Corp.
|
Mar 19, 2017 03:37PM
|
|
Re: A comment about market penetration
|
6
|
Resverlogix Corp.
|
Mar 20, 2017 04:25PM
|
|
Re: breaking news...Apple forms secret team to address Diabetes?
|
1
|
Resverlogix Corp.
|
Apr 13, 2017 10:18AM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
3
|
Resverlogix Corp.
|
May 10, 2017 03:26PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
1
|
Resverlogix Corp.
|
May 10, 2017 03:30PM
|
|
Pfizer enzalutimide perspective
|
5
|
Zenith Epigenetics
|
May 14, 2017 02:55PM
|
|
Re: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
|
4
|
Resverlogix Corp.
|
May 15, 2017 05:17PM
|
|
Re: Evacetrapib fails
|
2
|
Resverlogix Corp.
|
May 18, 2017 10:35AM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
2
|
Resverlogix Corp.
|
May 26, 2017 10:41AM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
|
Resverlogix Corp.
|
May 26, 2017 01:50PM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
|
Resverlogix Corp.
|
May 26, 2017 03:53PM
|
|
Re: More news on the way? They say things happen in 3s.....
|
6
|
Resverlogix Corp.
|
May 29, 2017 12:23PM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
5
|
Resverlogix Corp.
|
May 30, 2017 11:13AM
|
